Retreatment with peptide receptor radionuclide therapy (PRRT) in patients (p) with neuroendocrine tumors (NET): Spanish clinical experience from SEPTRALU national registry

被引：0

作者：

Hernando Cubero, J. ^{[1
]}

Lago, N. Martinez ^{[2
]}

Mitjavila, M. ^{[3
]}

Garcia-Burillo, A. ^{[4
]}

Pubul, V. ^{[5
]}

Bello, P. ^{[6
]}

Cano, J. M. ^{[7
]}

Llana, B. ^{[8
]}

Castellon, M. ^{[9
]}

Rodeno, E. ^{[10
]}

Pineiro, A. ^{[11
]}

Soldevilla, C. ^{[12
]}

Nevares, M. ^{[13
]}

Aller, J. ^{[14
]}

Anido Herranz, U. ^{[15
]}

Carnero Lopez, B. ^{[16
]}

Nogareda, Z. ^{[5
]}

Garcia Alvarez, A. ^{[17
]}

Jimenez Fonseca, P. ^{[18
]}

Capdevila Castillon, J. ^{[19
]}

机构：

[1] Vall dHebron Univ Hosp, Dept Med Oncol, Barcelona, Spain

[2] Hosp Arquitecto Marcide, CHUF Complejo Hosp Univ Ferrol, Med Oncol, Ferrol, Spain

[3] Hosp Univ Puerta Hierro, Nucl Med, Majadahonda, Spain

[4] Vall dHebron Univ Hosp, Nucl Med, Barcelona, Spain

[5] Complexo Hosp Univ Santiago Compostela, Nucl Med, Santiago De Compostela, Spain

[6] Hosp Univ & Politecn La Fe, Nucl Med, Valencia, Spain

[7] Hosp Gen Ciudad Real, Med Oncol Dept, Ciudad Real, Spain

[8] Hosp Univ Cent Asturias, Nucl Med, Oviedo, Spain

[9] Hosp Clin Univ Virgen de la Arrixaca, Nucl Med, El Palmar, Spain

[10] Hosp Univ Cruces, Nucl Med, Baracaldo, Spain

[11] Hosp Univ Virgen de las Nieves, Nucl Med, Granada, Spain

[12] Hosp Santa Creu & Sant Pau, Nucl Med, Barcelona, Spain

[13] Hosp Univ Burgos, Nucl Med, Burgos, Spain

[14] Hosp Univ Puerta De Hierro, Endocrinol, Majadahonda, Spain

[15] CHUS Complejo Hosp Univ Santiago de Compostela SE, Med Oncol, La Coruna, Spain

[16] Hosp Univ Lucus Augusti, Med Oncol, Lugo, Spain

[17] Vall dHebron Univ Hosp, Med Oncol Dept, Barcelona, Spain

[18] Hosp Univ Cent Asturias, Med Oncol, Oviedo, Spain

[19] Vall dHebron Univ Hosp, Vall dHebron Inst Oncol VHIO, Med Oncol, Barcelona, Spain

来源：

ANNALS OF ONCOLOGY | 2024年 / 35卷

关键词：

D O I：

10.1016/j.annonc.2024.08.1216

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

1157P

引用

页码：S756 / S756

页数：1

共 50 条

[1] Single Institution Experience with Peptide Receptor Radionuclide Therapy (PRRT) in Neuroendocrine Tumors (NET)
Duan, H.
Ninatti, G.
Girod, B.
Ferri, V
Guja, K.
Song, H.
Kunz, P.
Fisher, G.
Lagaru, A.
Mari, Aparici C.
NEUROENDOCRINOLOGY, 2020, 110 : 253 - 253
[2] Single institution experience with peptide receptor radionuclide therapy (PRRT) in neuroendocrine tumors (NET)
Duan, Heying
Ninatti, Gaia
Girod, Bradley
Ferri, Valentina
Kunz, Pamela L.
Fisher, George A.
Moradi, Farshad
Davidzon, Guido Alejandro
Franc, Benjamin Lewis
Iagaru, Andrei
Mari, Carina
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (04)
[3] Single Institution Experience With Peptide Receptor Radionuclide Therapy (PRRT) in Neuroendocrine Tumors (NET)
Duan, H.
Ferri, V.
Kunz, P.
Davidzon, G.
Nguyen, J.
Moradi, F.
Franc, B.
Iagaru, A.
Aparici, C. Mari
PANCREAS, 2021, 50 (03) : 456 - 456
[4] Peptide receptor radionuclide therapy (PRRT) for neuroendocrine tumors (NET): A single institution experience in the USA
Duan, H.
Ferri, V.
Kunz, P. L.
Fisher, G. A.
Moradi, F.
Davidzon, G. A.
Franc, B. L.
Iagaru, A. H.
Mari, C. Aparici
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2020, 47 (SUPPL 1) : S468 - S469
[5] Evaluation of toxicity in peptide receptor radionuclide therapy (PRRT) for neuroendocrine tumors (NET)
Duan, H.
Ferri, V.
Kunz, P. L.
Fisher, G. A.
Moradi, F.
Davidzon, G. A.
Franc, B. L.
Iagaru, A. H.
Mari, C. Aparici
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2020, 47 (SUPPL 1) : S471 - S472
[6] Evaluation of Toxicity in Peptide Receptor Radionuclide Therapy (PRRT) for Neuroendocrine Tumors (NET)
Duan, H.
Girod, B.
Ninatti, G.
Ferri, V
Kunz, P.
Fisher, G.
Moradi, F.
Davidzon, G.
Franc, B.
Lagaru, A.
Aparici, Mari C.
NEUROENDOCRINOLOGY, 2020, 110 : 252 - 252
[7] Patients with Advanced Neuroendocrine Tumors Treated with Peptide Receptor Radionuclide Therapy with 177Lu-DOTATE: Data from Spanish SEPTRALU Registry
Mitjavila, M.
Percovich, J. C.
Pombo Pasin, M. C.
Bello, P.
Arbizu, J.
Llana, B.
Riesco, M. C.
Muros, M. A.
Estenoz, J.
Rotger, A.
Aller, J.
Jimenez-Fonseca, P.
NEUROENDOCRINOLOGY, 2019, 108 : 223 - 223
[8] Peptide Receptor Radionuclide Therapy (PRRT) with 177Lu-DOTATATE (177Lu) Is Effective and Safe in Patients with Pretreated Metastatic Neuroendocrine Tumors: Data from Spanish SEPTRALU Registry
Bello, P.
Jimenez-Fonseca, P.
Percovich, J. C.
Anido Herranz, U.
Gajate, P.
Castellon, M.
Estorch, M.
Gonzalez, E.
Field, C.
Garcia Alonso, P.
Carmona-Bayonas, A.
Mitjavila, M.
NEUROENDOCRINOLOGY, 2019, 108 : 198 - 198
[9] Peptide receptor radionuclide therapy (PRRT) for neuroendocrine tumors (NET): A two-year single institution experience
Duan, Heying
Ninatti, Gaia
Girod, Bradley
Ferri, Valentina
Guja, Kip
Song, Hong
Kunz, Pamela
Fisher, George
Iagaru, Andrei
Aparici, Carina Mari
JOURNAL OF NUCLEAR MEDICINE, 2020, 61
[10] Retreatment PRRT with 177Lu-DOTATATE in patients with progressive neuroendocrine neoplasm: Spanish clinical experience from national registry
Mitjavila Casanovas, M.
Pubul, V.
Garcia-Burillo, A.
Bello, P.
Valverde, R.
Llana, B.
Pineiro, A.
Ardila, J.
Arbizu, J.
Soldevila, C.
Castellon, M.
Orduna, P.
Cano, J.
Garcia-Canamaque, L.
Nevares, M.
Balaguer, D.
Gomez-Sanchez, D.
Rodado, S.
Repetto, A.
Tabuenca, M.
Aller, J.
de la Rubia, M.
Carmona-Bayonas, A.
Jimenez-Fonseca, P.
Hernando, J.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2024, 51 : S126 - S126

← 1 2 3 4 5 →